Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Read and Learn - http://myscience.appliedbiosystems.com
Here's Pharm-Eco web site take a look - http://www.pharmeco.com/
Johnson Matthey becomes your strategic partner in pharmaceutical product development and production.
As your strategic partner, Johnson Matthey helps you develop and produce the world's highest quality active pharmaceutical ingredients, meet tight production deadlines and speed new products to market.
We assign a highly trained technical team to guide and assist you. Your Johnson Matthey scientific team is experienced in:
Sophisticated process development
State-of-the-art analytical methodologies
Rigid process validation procedures
Responsive customer service
Strict regulatory compliance
Shorten the bridge from laboratory to the marketplace. Find out how you may benefit from a Johnson Matthey partnership. Please contact us for more details or Call (856) 384-7001 (800) 444-8544 (toll-free from USA only)
Production Capabilities
The Johnson Matthey team helps you meet your production requirements - and your deadlines, offering:
Wide reactor capacity range: from 5 to 2,000 gallons (22 - 7,500 litres)
Strict cGMP control standards for laboratory production volumes
Materials of construction either in glass-lined or hastalloy C reactors
Multiple stand-alone trains ensure full range of scale-up equipment
Hydrogenation capabilities to 100 psi
Particle-size reduction equipment
All products are handled in Class 100,000 contamination-control rooms with HEPA filtered-air-handling systems
Ample warehouse facilities serve our customers' growing needs
Unrivalled security and materials control
Adherence to FDA's current Good Manufacturing Practice (cGMP) requirements including filing a Drug Master File (DMF) with the FDA and managing a pre-approval inspection
International compliance filing
Strict compliance with DEA manufacturing requirements for Class I through Class V controlled substances
Service
We listen and guide you
A special Johnson Matthey team works with you each step of the way from raw materials to finished, tested product.
We advise you and we resolve difficult synthetic process routes. Perhaps most important, we help you reduce new product development time.
Process development expertise
Your Johnson Matthey team is staffed heavily with Ph.D. level chemists with broad experience in organic and organometallic chemistry. A highly skilled team of scientists from Johnson Matthey's Chemical Process Research and Development (CPR&D) group works with you every step of the way offering innovative solutions to difficult synthetic processes.
Johnson Matthey: the competitive edge
Your success-driven Johnson Matthey team helps you produce the industry's highest quality products and deliver them on schedule.
Johnson Matthey bought Pharm-Eco also So Pharm-Eco right now is really Johnson Matthey
Ming, We must not forget Our CEO Richard Is co-owner of PharmEco Inc. in Mass. thats a big reason why he might be a investor with this comp. and there most likely more to this picture than we are seeing.
Yes Mike, thats very interesting a I dont know the answer to that either but got to go kids want to go to the park.Have a great day
Mike,I agree. Who is telling the truth and who do we listen to Tony or Richard. There's at least 2 different places where Tony has indicated eye and hair would be out in 2004.And i agree when you say "never mind about the original deinition" if they are going to release info. on a project we should not be getting one message from Tony and a different message from Richard. Its like they work for different comp.'s and dont know each other. I mean whats up with that.
And what about this from the USF Research Park.http://www.research.usf.edu/webcam/
There's 3 floors to this project and they dont even have the pillers up for the second floor.We have the exact same building going up here on campus and it has taken almost 2 years just to get 1& 2 floor pillers and outside walls up.There is no way Dnap is moving in next year or even the following year this project will take at least the next 2 years to complete.And by the way you think Richard came to Dnap Broke with no money in the Bank,than your a fool Richard was already a millionair before coming to Dnap he doesent need to use Dnap Shares to pay his way through life, wake up.
What kind of game is Dnap playing,leading us on to believe eye and hair color would contribute to 2004 revenue, when we read this in the news letter from the CEO.
"Over the next several years, we will continue to expand our products’ ability to provide an image of the individual that may include eye color, hair color and other phenotypic descriptors unique to the donor’s genetic heritage". I thought eye and hair was to be out this year 2004 !!! Not in several years !!!! IN SEVERAL YEARS !!!! What sort of crap is this. "That May Include" whats that mean - There's a chance it wont be include.Something is very wrong here.
From the July 2004 news letter - "Over the next several years, we will continue to expand our products’ ability to provide an image of the individual that may include eye color, hair color and other phenotypic descriptors unique to the donor’s genetic heritage". I thought eye and hair was to be out this year 2004 !!! Not in several years !!!! Also that research buld. their putting up in wont be ready for years there's no way their moving into it by next year, they dont even have the second floor up.
twelks, no it really doesn't matter now the right people have been contacted and there will be follow ups with them only.Fair well
Grateful, check this web site out - The Research Revolution - http://www.nvr.org/research_index.php?pro=research
Grateful,John Simich is - Research Revolution: Forensics, CSI Buffalo: Gene Squad
Presenter: Dr. John Simich, Asst. Laboratory Dir
Presenter Affiliation: Erie. Co. Central Police Services Forensics Lab
Location: Roswell Park Room, Abbott (Health Sci. Lib.)
Campus: South Campus
Date: 10/15/03
Time: 7:00 p.m. - 9:00 p.m.
Cost: Free, open to UB community and the public. Reservations required
Sponsor: University Libraries
Contact: Judith Adams-Volpe, 645-2756 x228 (adamsj@buffalo.edu)
"Research Revolution: Science and the Shaping of Modern Life" is a video and discussion series that encourages the public to examine and discuss the effects of science and technology on their daily lives. "Forensics, CSI Buffalo" features Dr. John Simich, Asst. Laboratory Dir., Erie County Central Police Services Forensics Lab, and the film, "Gene Squad."
Reservations required.
See Research Revolution Web site, or contact Judy Adams-Volpe, 645-2756 x228, adamsj@buffalo.edu.
Gmed ===
Outstanding Shares = 161,452,849
Restricted Shares = 57,642,849
Float = 103.8 Million as of 3-4-04
Gmed ===
Outstanding Shares = 161,452,849
Restricted Shares = 57,642,849
Float = 103.8 Million as of 3-4-04
,,hu
A 30 day increase by 117,980,195 outstanding And
increased by 104,857,171 Restricted, What happen ? They dont need money so what happen ?
Dnaprint Genomics -
Outstanding Shares - 563,052,461
Restricted Shares - 76,537,314
Float - 486.5 Million as of 2-26-04
CIK = 1127354
###########################################
Dnaprint Genomics : as of 4-5-04
Outstanding Shares = 681,032,656
Restricted Shares = 181,394,485
Float = 499,638,171
increase by 117,980,195 outstanding
increased by 104,857,171 Restricted
What could this mean ????? IBM Maybe
computer software for user-friendly applications of population genetic principles in DNA data bases maintained by the Criminal Justice System of the US Government - - Now guess where this came from ? Do you know because there is a lot more !!!
gunn ya thats why Dnap want nothing to do with you all They shut the door on you all because of the attitude you all have I'm done with ya over and out so is Dnap.
You know i think this will be my last post you people must not live in my part of the country because we value all these thing for many different reasons,you dont. So i'll leave you with this last contribution and say fair well.--- Retinome. As of March 18, 2002, Retinome was 98% accurate predicting
eye color shade, and 75% accurate predicting the precise eye color within a shade, where light shade is blue, green and hazel eyes and dark is brown and black. We have finished a screen of three more genes in an attempt to increase the accuracy for predicting actual eye color, and identified another gene whose variant sequences are associated with eye color.
Intellectual Property and Products. From the Filings:
Phenome Database. We have developed unique and comprehensive SNP databases. An "SNP" is a single nucleotide polymorphism - a common DNA sequence variation that has great significance for biomedical research. We have developed our SNP databases through the use of proprietary data mining techniques, software and biochemical research and development. To date, we have discovered several thousand SNP sequences useful for drug interactivity screening. Our databases are
4
fully annotated, and contain relevant LocusLink, Medline, UniGene,Entrez, and PubMed information. Another factor that distinguishes our database is that it contains a molecular address for each target SNP that enables rapid application to microchip based screening platforms. Most of our data and annotation do not currently exist in any public database, and we enjoy their exclusive use.
Who's next Spook we have a little support team here. If this is so and its allowed to continue than this board will become like RB and then theres no point to continue.
ebo783 are you 66 - Because the last time 66 posted about me you showed up in support of him.
eb0783, First and formost i am not anyone here's secretary i refuse to do all the leg work use your research skills to follow up on any further info. you need. Now I told you this before and you still dont get it. I am not your secretary and IT IS NOT A REASON TO BASH ME BECAUSE I DONT DOT ALL THE i's AND CROSS ALL THE T's. IF you chose to use this as a reason to bash me than you and i will have a big fight. I share info. in good faith if you chose to find falt with it to bash me further than you show me your real position here and than you will lose my respect. Now for the last time i am not your secretary do your own leg work.
66 - If you keep up your attacks I will report you as a trouble maker. KEEP YOUR POSTS ON DNAP and keep them friendley or you will be reported.
Let me give you some advise you won't have to pay for, for a change.If your having feelings of inadequacy,or feeling incompetent or incomplete try educating your self to a level that is self gratifying rather than putting others down in a futile attempt to raise yourself above others. It is very bad for your image to attack others just to feel good about yourself.There are many resources available to help you along the way, collage is a good start. But me thinks you are in fact incorrigible and so confined to all the fruit there in.Using for your tools through life a Base,cynical,approach only makes your view insipid Prattle and brings you down to a lower level,it brings no good fruit to eat from,no good friends, you sow contempt for your self in this.We live in a great land where almost anyone can learn and grow and reach for the stars if he makes the effort to do so.Dont try to get ahead by stepping on others but by upgrading your self in knowledge, wisdom, and love.Dont get me wrong here i have no problems getting into a scrap with someone {pushed hard enought} but real strength comes from self control guided by the knowledge,wisdom,and Love of God, and self effort.Old knowledge is hard for you to hear you say well then you better through out the bible and any other resource material keeped around the house.And what of those who are new to the board, you wish to take their right to know away because you deam it to be old news.Your use of - it being Old News - to show contempt for some one is only telling of your personality and ablity to not get along with others than it is a reflection of a desire for updated info.No info. at all, is better than Old info. you Sir are simply incorrigible.Have you forgotten the teachings of Christ and the Bible or that doesn't apply here. The bible says do not through pearls to swine at some point it must be considered. Are you swine ? Than I should take my leave of you.
66 - if you keep up your attacks I will report you as a trouble maker. KEEP YOUR POSTS ON DNAP or you will be reported
66 - This board is for info. on Dnap not the attacks you try to put on others by telling IVRT,DougS, or Theo what to do or what the rules are.66 - What is it you dont get brainless ONLY INFO. ON DNAP AND A FRIENDLY ATTITUDE IS ACCEPTED HERE.NONE OF YOUR POSTS SHOW THIS UNDERSTANDING. Get with the program.
Gcbr,you and these other posts are not required to be impressed but you are required to extend your hand in friendship with respect, and since you and your kind choose to respond in this way,i shall take my leave of the condescending and arrogance.66fan last few post here have only showed contempt for me as does yours.What makes you think I would be looking to impress the likes of you and 66fan anyway believe me i wouldn't waste my time with either of you.But bad apples always spoil the lot sooner or later so i will leave before any of your input spills over on me.
Well looks like from the response here most sold out.Its just little old me left,well i'm long and strong,ya, my wife tells me that all the time,ya,how you like that. LOL Good night.
How many think eye color will not be out for a while,3 or 4 more months
how many think news on eye color will be followed close by another News release.How many think there will only be news out on eye color and thats it.
Ok .20 cents on eye color with 80 to 100 million in volume the first day.After that who knows.
How high do you think we can go on eye color ? I'm hoping at least .17 cents
How far away is the eye color {Retinome {TM}} not far end of the Month.
Pharmacogenomics Approach to the Treatment and Management of Ovarian Cancer.
PURPOSE:
Many different drugs are available for cancer patients. Some of these drugs work better than others. Scientists believe that differences among patients may explain why some drugs work on some people and others do not. It is thought that these differences might best be explained by differences in genetic makeup among people.
In other words, the genes that make us who we are -- determine height, eye color and other traits -- might also explain how different people respond to different medical treatments.
The purpose of this project is to study the genes that might be involved when your body processes the various cancer medicines you were, or are being treated with.
In other words, by studying your genes we hope to learn how they cause your body to respond to the chemotherapy you are receiving or have received.
With this improved understanding, we hope to be able in the future to design drugs that will be most appropriate for specific patients. That is, we hope that in the future we will be able to use patients' genetic makeup to provide medicines that are customized or targeted toward their particular needs.
PROCEDURES:
If you decide to participate in this study, a laboratory technician will draw 2 extra tablespoons of blood while blood is being taken as part of regular testing. (You will not be stuck with a needle any more than is already required for treatment and related testing.) If tissue is available from your surgery, a small sample will be collected for this study. No extra tissue will be removed for the purpose of this study. These samples will be used to prepare your genetic material for the test.
If you are interested in participating in this study, click on the link below to request an appointment. Be sure to include the name of the study in the “Reason for Appointment” field. REQUEST AN APPOINTMENT
Development of a BRCA1 and BRCA2 mutation screening assay for women of African descent.
Abstract: DESCRIPTION: (Adapted from investigator's abstract)
The long term objective of this application is to develop and to clinically validate a screening panel for specific BRCA1 and BRCA2 mutation/genetic variants in women of African descent with breast cancer. The development of such panel will allow its incorporation into clinical practice with clear improvement of genetic counseling for this minority population. African-American women under age 50 in the United States have the highest rate of new cases of breast cancer in the nation. In addition, African-American women of all ages have a larger percentage of poorly differentiated breast cancer that is more likely to occur at an earlier age, and to be estrogen and progesterone receptor negative - all factors associated with more aggressive tumorgenicity. Based on this preliminary data and a thorough review of all published English literature, we have identified thirteen mutations and thirteen unclassified variants in BRCA1 and six mutations and ten variants in BRCA2. A screening panel for such BRCA1 and BRCA2 mutations/variants will be designed to develop an efficient assay for eventual use in clinical practice. This assay is based on a combination of multiplex PCR and multiplex SSCP in order to provide a high throughput screening method for the above designated genetic alterations. SSCP variants will be further investigated by DNA sequencing to confirm the exact genetic change. The development of this screening panel will have an important impact on genetic counseling for women of African descent. It may also be helpful in anticipating the design of preventive strategies (mammography, chemoprevention, or prophylactic surgery) and in selecting appropriate therapeutic protocols for this under-served and under-investigated patient population.
PHARMACOGENICS APPROACH TO THE TREATMENT AND MANAGEMENT OF OVARIAN CANCER.
PURPOSE:
Many different drugs are available for cancer patients. Some of these drugs work better than others. Scientists believe that differences among patients may explain why some drugs work on some people and others do not. It is thought that these differences might best be explained by differences in genetic makeup among people.
In other words, the genes that make us who we are -- determine height, eye color and other traits -- might also explain how different people respond to different medical treatments.
The purpose of this project is to study the genes that might be involved when your body processes the various cancer medicines you were or are being treated with.
In other words, by studying your genes we hope to learn how they cause your body to respond to the chemotherapy you are receiving or have received.
With this improved understanding, we hope to be able in the future to design drugs that will be most appropriate for specific patients. That is, we hope that in the future we will be able to use patients' genetic makeup to provide medicines that are customized or targeted toward their particular needs.
PROCEDURES:
If you decide to participate in this study, a laboratory technician will draw 2 extra tablespoons of blood while blood is being taken as part of regular testing. (You will not be stuck with a needle any more than is already required for treatment and related testing.) If tissue is available from your surgery, a small sample will be collected for this study. No extra tissue will be removed for the purpose of this study. These samples will be used to prepare your genetic material for the test.
If you are interested in participating in this study, click on the link below to request an appointment. Be sure to include the name of the study in the “Reason for Appointment” field. REQUEST AN APPOINTMENT
A PHASE II TRIAL OF THALOMID IN COMBINATION WITH TAXOL AND CARBOPLATIN AS FIRST LINE THERAPY FOR ADVANCED STAGE (III AND IV) SUBOPTIMALLY DEBULKED PATIENTS WITH HISTOLOGIC PROVEN EPITHELIAL OVARIAN CANCER
PRINCIPAL INVESTIGATOR: Ramin Mirhashemi, M.D.
PATIENT INFORMATION (GENERAL)
You are being asked to participate in a clinical research study. You have the option not to participate. Please take your time making your decision. You may discuss it with your family and friends. This study is being carried out under the sponsorship of Bristol-Myers Squibb, the pharmaceutical company which has developed Taxol and Carboplatin, and Celgene, the pharmaceutical company which has developed Thalomid (Thalidomide). In general the research carried out compares the effectiveness of different methods of treating cancer of the female genital organs. In this manner, the best treatment—whether old or new—can be established.